-
Hoofnagle
JH, Mullen KD, Jones DB, et al. Treatment of chronic
non-A, non-B hepatitis with recombinant human alpha
interferon. N.Engl.J.Med 1986; 315: 1575-1578.
-
Di
Bisceglie AM, Martin P, Kassianides C, et al.
Recombinant interferon alpha therapy for chronic
hepatitis C. A randomized, double-blind, placebo-controlled
trial. N.Engl.J.Med 1989; 321: 1506-1510.
-
Poynard T,
Leroy V, Cohard M, et al. Meta-analysis of
interferon randomized trials in the treatment of
viral hepatitis C : effects of dose and duration.
Hepatology 1996; 24: 778-789.
-
McHutchison JG, Gordon SC, Schiff ER, et al.
Interferon alpha-2b alone or in combination with
ribavirin as initial treatment for chronic hepatitis
C. N.Engl.J.Med 1998; 339: 1485-1492.
-
Poynard T,
Marcellin P, Lee SS, et al. Randomized trial of
interferon alpha 2b plus ribavirin for 48 weeks or
for 24 weeks versus interferon alpha 2b plus placebo
for 48 weeks for treatment of chronic infection with
hepatitis C virus. Lancet 1998; 352: 1426-1432.
-
Manns MP,
McHutchison JG, Gordon SC, et al. Peginterferon
alpha-2b plus ribavirin compared with interferon
alpha-2b plus ribavirin for initial treatment of
chronic hepatitis C : a randomized trial. Lancet
2001; 358: 958-965.
-
Fried MW,
Shiffman ML, Reddy KR, et al. Combination of
Peginterferon alpha-2a plus ribavirin in patients
with chronic hepatitis C virus infection.
N.Engl.J.Med 2002; 347: 975-982.
-
Hadziyannis SJ, Sette H Jr, Morgan TR, et al.
Peginterferon-alpha-2a and ribavirin combination
therapy in chronic hepatitis C. A randomized study
of duration and ribavirin dose. Ann. Intern.Med
2004; 140: 346-355.
-
Buti M,
San Miguel R, Brosa M, et al. Estimating the impact
of hepatitis C virus therapy on future liver-related
morbidity, mortality and costs related to chronic
hepatitis C. J.Hepatol 2005; 42: 639-645.
-
Layden-Almer
JE, Layden TJ. Viral kinetics in hepatitis C virus :
special patient populations. Semin Liver Dis 2003;
23(Suppl.1): 29-33.
-
Layden-Almer
JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ.
Viral dynamics and response differences in HCV-
infected African American and white patients treated
with IFN and ribavirin. Hepatology 2003; 37:
1343-1350.
-
Davis GL.
Monitoring of viral levels during therapy of
hepatitis C. Hepatology 2002; 36: S145-S151.
-
Ferenci P.
Predictors of response to therapy for chronic
hepatitis C. Sem.L.Dis 2004; 24 (Suppl.2): 25-31.
-
Davis GL,
Lau JY. Factors predictive of a beneficial response
to therapy of hepatitis C. Hepatology 1997; 26:
122S-127S.
-
Poynard T,
McHutchison J, Goodman Z, et al. Is an a la carte
combination interferon alpha-2b plus ribavirin
regimen possible for the first line treatment in
patients with chronic hepatitis C ? Hepatology 2000;
31: 211-218.
-
Lee SS,
Heathcote EJ, Reddy KR, et al. Prognostic factors
and early predictability of sustained viral response
with peginterferon alpha-2a (40 KD). J.Hepatol 2002;
37: 500-506.
-
Pawlotsky
JM. Mechanism of antiviral treatment efficacy and
failure in chronic hepatitis C. Antiviral Res 2003;
59: 1-11.
-
Farci P,
Strazzera R, Alter HJ, et al. Early changes in
hepatitis C viral quasispecies during interferon
therapy predict the therapeutic outcome.
Proc.Natl.Acad.Sci USA 2002; 99: 3081-3086.
-
Rubbia-Brandt
L, Giostra E, Mentha G, Quadri R, negro F.
Expression of liver steatosis in hepatitis C virus
infection and pattern of response to alpha
interferon. J.Hepatol 2001; 35: 307.
-
Cacciola
I, Pollicino T, Squadrito G, et al. Occult hepatitis
B virus infection in patients with chronic hepatitis
C liver disease. N.Engl.J.Med 1999; 341: 22-26.
-
Soriano V,
Sulkowski M, Bergin C, et al. Care of patients with
chronic hepatitis C and HIV co-infection :
recommendations from the HIV-HCV International
Panel. AIDS 2002; 16: 813-828.
-
Bekkering
FC, Brouwer JT, Leroux-Roels G, et al. Ultra rapid
hepatitis C virus clearance by daily high-dose
interferon in non-responders to standard therapy. J.
Hepatol 1998; 28: 960-964.
-
Neumann AU,
Lam NP, Dahari H, et al. Hepatitis C viral dynamics
in vivo and the antiviral efficacy of interferon-alpha
therapy. Science 1998; 282: 103-107.
-
Neumann AU,
Lam NP, Dahari H, et al. Differences in viral
dynamics between genotypes 1 and 2 of Hepatitis C
virus.J. Infect Dis 2000; 182: 28-35.
-
Zeuzem S,
Herrmann E, Lee JH, et al. Viral kinetics in
patients with chronic hepatitis C treated with
standard or peginterferon alpha 2a. Gastroenterology
2001; 120: 1438-1447.
-
Pawlotsky
JM. Current and future concepts in hepatitis C
therapy.Sem.L.Dis 2005 ; 25 :72-83.
-
Moreaux X,
Poggi C, Chollet L, et al. Eradication du virus de
l’hepatite C après 3 mois de traitement par
interféron alpha pour une hépatite chronique virale
C (letter). Gastroenterol Clin Biol 2001 ; 25 :
715-716.
-
Hrycewycz
N, Sandres K, Barangue K, et al. Guérison d’une
hépatite chronique virale C chez un malade non
répondeur à l’interféron alpha 2b, après 3 mois de
traitement par l’association interféron alpha 2b et
ribavirine (letter). Gastroenterol Clin Biol 2001 ;
25 : 1041-1042.
-
Nousbaum
JB, Cadranel JF, Savary O, et al. Sustained
virological response after a short course of
treatment with interferon and ribavirin in two
chronic hepatitis C patients. J.Hepatol 2003; 39:
655-659.
-
Ferenci P.
Predicting the therapeutic response in patients with
chronic hepatitis C: the role of viral kinetic
studies. J.Antimicrob Chemother 2004; 53: 15-18.
-
Ferenci P,
Fried MW, Shiffman ML, et al. Predicting sustained
virological responses in chronic hepatitis C
patients treated with peginterferon alfa-2a (40KD)/
ribavirin. J.Hepatol 2005; 43: 425-433.
-
Dalgard O,
Bjoro K, Hellum KB, et al. Treatment with pegylated
interferon and ribavirin in HCV infection with
genotype 2 or 3 for 14 weeks : a pilot study.
Hepatology 2004; 40: 1260-5.
-
Mangia A,
Santoro R, Minerva N, et al. Peginterferon alfa-2b
and ribavirin for 12 vs.24 weeks in HCV genotype 2
or 3. N.Engl J.Med 2005; 352: 2609-17.
-
Zeuzem S,
Hulterantz R, Bourliere M, et al. Peginterferon
alfa-2b plus ribavirin for treatment of chronic
hepatitis C in previously untreated patients
infected with HCV genotypes 2 or 3. J.Hepatol 2004;
40: 993-9.
-
Zeuzem S,
Buti M, Ferenci P, et al. Efficacy of 24 weeks
treatment with peginterferon alfa-2b plus ribavirin
in patients with chronic hepatitis C infected with
genotype 1 and low pretreatment viremia. J.Hepatol
2006; 44: 97-103.
-
Zeuzem S,
Pawlotsky JM, Lukasiewicz E, et al. International,
multicenter, randomized, controlled study comparing
dynamically individualized versus standard treatment
in patients with chronic hepatitis C. J.Hepatol
2005; 43:250-257.
-
Craxi A,
Camma C. Treating patients with HCV genotype 1 and
low viraemia: More than meets the eye. J.Hepatol
2006; 44: 4-7.
